<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium polystyrene sulfonate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium polystyrene sulfonate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium polystyrene sulfonate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11914" href="/d/html/11914.html" rel="external">see "Sodium polystyrene sulfonate: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12799" href="/d/html/12799.html" rel="external">see "Sodium polystyrene sulfonate: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F222030"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Kalexate [DSC];</li>
<li>Kayexalate [DSC];</li>
<li>Kionex [DSC];</li>
<li>SPS</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52914223"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Kayexalate</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F222046"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidote;</li>
<li>
                        Potassium Binder</li></ul></div>
<div class="block doa drugH1Div" id="F222033"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9b5810b4-b874-43a4-be72-5d6c74de492e">Hyperkalemia, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia, chronic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Use has been associated with an increased risk of GI adverse events, including intestinal necrosis, especially when administered with sorbitol; concomitant administration of sorbitol is not recommended. Prior to use, carefully assess risk versus benefit of therapy and consider alternative agents (eg, patiromer, sodium zirconium cyclosilicate) when feasible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31180477','lexi-content-ref-31180445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31180477','lexi-content-ref-31180445'])">Ref</a></span>). Avoid use (with or without sorbitol) in patients with risk factors for constipation or impaction (eg, history of impaction, chronic constipation, previous bowel surgery, inflammatory bowel disease); discontinue use if constipation occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 15 g 1 to 4 times daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal:</b> 30 to 50 g every 6 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="637f3b98-5df7-446f-8c61-563a0b944ec9">Hyperkalemia, severe/emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia</b>
<b>, severe/emergent (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Due to rare but significant complications, including intestinal necrosis (with or without sorbitol use), strongly consider other therapies for elimination of potassium, unless the patient meets <b>ALL </b>of the following criteria: Patient has potentially life-threatening hyperkalemia; dialysis is not readily available; newer cation exchangers (eg, sodium zirconium cyclosilicate) are not available; other therapies to eliminate potassium from body have failed or are not possible (eg, diuretics, rapid restoration of kidney function) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1','lexi-content-ref-31180445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1','lexi-content-ref-31180445'])">Ref</a></span>). <b>Safety:</b> Do not administer (with or without sorbitol) to the following patients due to the potential increased risk of intestinal necrosis: Postoperative patients, patients with an ileus, patients with constipation or at risk of becoming constipated (eg, due to opioid use), patients with a large or small bowel obstruction, patients with underlying bowel disease (eg, ulcerative colitis, <i>Clostridioides</i>
<i>difficile</i> colitis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1','lexi-content-ref-31180445']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1','lexi-content-ref-31180445'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral (preferred route):</b> 15 to 30 g once; may repeat up to 4 times per day as needed based upon serum potassium levels. Maximum daily dose: 60 g/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26327703','lexi-content-ref-23255245','lexi-content-ref-31706619','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26327703','lexi-content-ref-23255245','lexi-content-ref-31706619','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Rectal retention enema:</b> 30 to 50 g every 2 to 6 hours, as needed, based upon serum potassium levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mount.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mount.1','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Concomitant administration of sorbitol is not recommended.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50992124"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be dialyzed: No supplemental dose or dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed: No dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (not systemically absorbed) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989361"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F222034"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F222042"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12799" href="/d/html/12799.html" rel="external">see "Sodium polystyrene sulfonate: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc1818a0-0f66-4545-a67b-d6b92f0fe2c5">Hyperkalemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia: </b>Limited data available: <b>Note: </b>Typically not first-line; used when necessary to increase potassium excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21181208'])">Ref</a></span>). Due to delayed onset of action, sodium polystyrene sulfonate should not be used an emergency treatment for life-threatening hyperkalemia.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Weight-based dosing</i>: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Oral, nasogastric: 1 g/kg/dose every 6 hours; maximum dose: 15 g/dose; <b>Note:</b> Oral route more effective than rectal and is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fuhrman.1','lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fuhrman.1','lexi-content-ref-21181208'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Rectal: 1 g/kg/dose every 2 to 6 hours; maximum dose range: 30 to 50 g/dose; retain at least 15 to 60 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fuhrman.1','lexi-content-ref-21181208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fuhrman.1','lexi-content-ref-21181208'])">Ref</a></span>); <b>Note:</b> Sorbitol-free preparations are preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fuhrman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fuhrman.1'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Exchange-ratio based dosing</i>: Infants and small children: Oral, nasogastric, rectal: 1 mEq K<sup>+</sup>/g of sodium polystyrene sulfonate resin as the basis for calculation.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3a39111-1204-4d70-bee1-364829143150">Pretreatment of formula or expressed breast milk; decrease potassium load for renal failure patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pretreatment of formula or expressed breast milk; decrease potassium load for renal failure patients:</b> Limited data available; various approaches reported: Infants and Children:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Infant/Enteral formula</i>: 0.5 to 2.6 g/100 mL of formula (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23329388','lexi-content-ref-23707305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23329388','lexi-content-ref-23707305'])">Ref</a></span>) <b>or</b> 0.25 to 1g/mEq K<sup>+ </sup>content of formula (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10649740','lexi-content-ref-25930981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10649740','lexi-content-ref-25930981'])">Ref</a></span>), adjust dose based on patient serum potassium trends. After addition of the resin, shake vigorously to mix, allow to sit under refrigeration for 30 to 60 minutes, then decant liquid for feed and leave precipitate at the bottom. The extent of potassium removal depends on the formula; in one trial, Similac PM 60/40 samples showed significant decreases at additive amounts of 0.25 to 1 g/mEq K<sup>+</sup> content of formula versus Suplena which only showed significant reduction of K<sup>+</sup> concentrations in the formula at 1 g/mEq K<sup>+</sup> content of formula (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25930981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25930981'])">Ref</a></span>). Other electrolyte concentrations may also be decreased (eg, Ca, Mg, Cu, Zn) and significant increases in sodium concentrations of the formula were consistently reported; patients should be monitored closely.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Expressed breast milk:</i> Usual dose: ~1 g/100 mL; adjust based on patient serum potassium trends; reported dose range: 0.4 to 1.5 g/100 mL of expressed breast milk. After addition of the resin, shake vigorously to mix, allow to sit under refrigeration for 60 minutes, then decant liquid for infant feed and leave precipitate at the bottom. In addition to decreasing the potassium load of the feed (subsequently patient's serum K) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23707305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23707305'])">Ref</a></span>), other electrolyte concentrations may also be decreased (eg, Ca, Mg, Cu, Zn) and sodium concentrations (breast milk and serum) increased; patients should be monitored closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23707305']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23707305'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160218"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; risks of gastrointestinal adverse effects are greater in patients with renal insufficiency or failure.</p></div>
<div class="block dohp drugH1Div" id="F51160219"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F222002"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Alkalosis (Kakajiwala 2017), hypernatremia (Angel-Korman 2022), hypocalcemia (Kakajiwala 2017), hypokalemia (Angel-Korman 2022), hypomagnesemia, sodium retention</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Anorexia, bezoar formation (Croitoru 2015), colitis (Dos Santos 2021), constipation, diarrhea (Nepal 2010), fecal impaction, gastric irritation, gastrointestinal hemorrhage (Dantas 2021), gastrointestinal necrosis (including esophageal necrosis, intestinal necrosis) (Almulhim 2018, Garcia Rodriguez 2020, Klasen 2021), gastrointestinal perforation (Faucon 2018, Piron 2018), gastrointestinal ulcer (Albeldawi 2014), intestinal obstruction, ischemic colitis (Edhi 2018), nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:2em;">Nervous system: Foreign body reaction (Zaidan 2013)</p></div>
<div class="block coi drugH1Div" id="F222018"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to sodium polystyrene sulfonate, polystyrene sulfonate resins or any component of the formulation; hypokalemia (excluding Kayexalate); obstructive bowel disease; neonates with reduced gut motility; oral administration in neonates; rectal administration in neonates (sorbitol-containing formulations <b>only</b>)</p></div>
<div class="block war drugH1Div" id="F222000"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aspiration: Acute bronchitis and bronchopneumonia caused by inhalation of sodium polystyrene sulfonate particles have been reported; patients with impaired gag reflex, altered level of consciousness or patients prone to regurgitation may be at increased risk. Administer with the patient in an upright position.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte disturbances: Severe hypokalemia may occur; frequent monitoring of serum potassium is recommended within each 24-hour period; ECG monitoring may be appropriate in select patients. Cation-exchange resins may also affect other cation concentrations, possibly resulting in decreased serum magnesium and calcium.</p>
<p style="text-indent:-2em;margin-left:4em;">• Fecal impaction: Large oral doses may cause fecal impaction (especially in elderly); rectal administration has been associated with fecal impaction in children.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intestinal necrosis: Intestinal necrosis (including fatalities) and other serious gastrointestinal events (eg, bleeding, ischemic colitis, perforation) have been reported, especially when administered with sorbitol; concomitant administration of sorbitol is not recommended. Increased risk may be associated with a history of intestinal disease or surgery, hypovolemia, prematurity, and renal insufficiency or failure. Strongly consider other therapies for elimination of potassium, unless the patient meets <b>ALL </b>of the following criteria: Patient has potentially life-threatening hyperkalemia; dialysis is not readily available; newer cation exchangers are not available; other therapies to eliminate potassium from body have failed or are not possible (eg, diuretics, rapid restoration of kidney function) (Mount 2022; Parks 2019). Do not administer (with or without sorbitol) to the following patients due to the potential increased risk of intestinal necrosis: Postoperative patients; patients with an ileus; patients with constipation or at risk of becoming constipated (eg, due to opioid use); patients with a large or small bowl obstruction; patients with underlying bowel disease (eg, ulcerative colitis, <i>Clostridioides</i>
<i>difficile</i> colitis) (Mount 2022; Parks 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with severe heart failure and/or hypertension; sodium load may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edema: Use with caution in patients with edema; sodium load may exacerbate condition.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with kidney impairment; risks of GI adverse effects are greater in patients with kidney impairment or failure.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Higher doses in older adults may result in fecal impaction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Oral administration in neonates and use in neonates with reduced gut motility (postoperatively or drug-induced) is contraindicated. Rectal administration of sorbitol-containing formulations in neonates is also contraindicated. Use with caution in premature or low-birth-weight infants. Use with caution in children when administering rectally; excessive dosage or inadequate dilution may result in fecal impaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Effective lowering of serum potassium from sodium polystyrene sulfonate may take hours to days after administration; consider alternative measures (eg, dialysis) or concomitant therapy (eg, IV sodium bicarbonate) in situations where rapid correction of severe hyperkalemia is required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Enema vs oral administration: Enema will reduce the serum potassium faster than oral administration, but the oral route will result in a greater reduction over several hours.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878637"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F222010"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Powder, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Kalexate: (454 g [DSC]) [sorbitol free; contains sodium 100 mg (4.1 mEq)/g]</p>
<p style="text-indent:-2em;margin-left:4em;">Kayexalate: (453.6 g [DSC]) [contains sodium 100 mg (4.1 mEq)/g]</p>
<p style="text-indent:-2em;margin-left:4em;">Kionex: (454 g [DSC]) [contains sodium 100 mg (4.1 mEq)/g]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: (15 g, 453.6 g, 454 g)</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Kionex: 15 g/60 mL (60 mL [DSC], 473 mL [DSC]) [contains alcohol, usp, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium 1500 mg (65 mEq)/60 mL, sorbitol; raspberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">SPS: 15 g/60 mL (60 mL, 120 mL, 473 mL) [contains alcohol, usp, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium 1500 mg (65 mEq)/60 mL, sorbitol; cherry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 15 g/60 mL (60 mL, 480 mL, 500 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Suspension, Rectal:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 30 g/120 mL (120 mL [DSC]); 50 g/200 mL (200 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F221996"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F222021"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension</b> (SPS Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">15 g/60 mL (per mL): $1.21</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F222015"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral or NG:</b> Administer orally or via NG tube with patient in an upright position at least 3 hours before or 3 hours after other medications (patients with gastroparesis may require a 6 hour separation). <b>Do not mix in orange juice or in any fruit juice known to contain potassium.</b> Shake the suspension well prior to administration. Chilling the oral mixture will increase palatability. Sodium polystyrene sulfonate suspension may also be added to the patient's food (with the exception of potassium-containing food such as bananas and orange juice).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rectal:</b> Administer cleansing enema first. Administer sodium polystyrene sulfonate as a warm emulsion (body temperature). During administration, the solution should be agitated gently. Retain the enema in the colon for at least 30 to 60 minutes and for several hours, if possible. Once retention time is complete, irrigate the colon with a nonsodium-containing solution to remove resin.</p></div>
<div class="block admp drugH1Div" id="F52613871"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral or NG: Administer orally or via NG tube with patient in an upright position at least 3 hours before or 3 hours after other medications (patients with gastroparesis may require a 6 hour separation). Do not mix in orange juice or any fruit juice known to contain potassium.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Shake commercially available suspension well before use.<b></b>Chilling the oral mixture will increase palatability.</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for suspension: Powdered resin must be mixed with water or syrup prior to administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Rectal: Route is less effective than oral administration. Administer cleansing enema first. Each dose of the powder for suspension should be suspended in an aqueous vehicle and administered as a warm emulsion (body temperature). The commercially available suspension should also be warmed to body temperature. During administration, the solution should be agitated gently. Retain enema in colon: Neonates: 30 minutes; in older patients: At least 30 to 60 minutes and for several hours, if possible. Once retention time is complete, irrigate colon with a nonsodium-containing solution to remove resin.</p></div>
<div class="block use drugH1Div" id="F222014"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Hyperkalemia, chronic: </b>Treatment of hyperkalemia.</p></div>
<div class="block off-label drugH1Div" id="F56430984"><span class="drugH1">Use: Off-Label: Adult</span><p>Hyperkalemia, severe/emergent</p></div>
<div class="block mst drugH1Div" id="F222054"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Kayexalate [DSC] may be confused with Kaopectate, Kay Ciel</p>
<p style="text-indent:-2em;margin-left:4em;">Sodium polystyrene sulfonate may be confused with calcium polystyrene sulfonate</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatric patients: High-risk medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">KIDs List: Sodium polystyrene sulfonate, when used in very low birthweight neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be avoided due to risk of colonic perforation (weak recommendation; low quality of evidence) (PPA [Meyers 2020]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Always prescribe either one-time doses or as a specific number of doses (eg, 15 g q6h x 2 doses). Scheduled doses with no dosage limit could be given for days leading to dangerous hypokalemia.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Kionex [US] may be confused with Kinex brand name for biperiden [Mexico]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300068"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F222004"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. Specifically, the risk of  metabolic alkalosis may be increased. Antacids may diminish the therapeutic effect of Sodium Polystyrene Sulfonate.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Laxatives (Magnesium Containing): May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis. Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Sodium Polystyrene Sulfonate may decrease the serum concentration of Lithium.  Management: Consider separating administration of lithium from administration of oral sodium polystyrene sulfonate by at least 6 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meloxicam: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of meloxicam oral suspension (which contains sorbitol) may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sorbitol: May enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tenapanor: Sodium Polystyrene Sulfonate may diminish the therapeutic effect of Tenapanor.  Management: Separate administration of tenapanor and sodium polystyrene sulfonate (SPS) by at least 3 hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Sodium Polystyrene Sulfonate may decrease the serum concentration of Thyroid Products.  Management: Consider administering thyroid products at least 4 hours prior to sodium polystyrene sulfonate. Monitor for signs and symptoms of hypothyroidism with concomitant use.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F13851578"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Some liquids may contain potassium: Management: Do not mix in orange juice or in any fruit juice known to contain potassium.</p></div>
<div class="block pri drugH1Div" id="F11510210"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Animal reproduction studies have not been conducted. Sodium polystyrene sulfonate is not absorbed systemically following oral or rectal administration. Use during pregnancy is not expected to result in significant exposure to the fetus.</p></div>
<div class="block brc drugH1Div" id="F20688449"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Sodium polystyrene sulfonate is not absorbed systemically. Breastfeeding is not expected to result in significant exposure to a breastfed child.</p></div>
<div class="block dic drugH1Div" id="F222022"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Do <b>not</b> mix in orange juice or in any fruit juice known to contain potassium. Some products may contain sodium.</p></div>
<div class="block mop drugH1Div" id="F222008"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum electrolytes (potassium, sodium, calcium, magnesium); ECG in select patients; signs/symptoms of fluid overload in patients sensitive to sodium intake (eg, heart failure, hypertension, edema); constipation.</p></div>
<div class="block rer drugH1Div" id="F222011"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Serum potassium: Adults: 3.5 to 5 mEq/L</p></div>
<div class="block pha drugH1Div" id="F221999"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Removes potassium by exchanging sodium ions for potassium ions in the intestine (especially the large intestine) before the resin is passed from the body; the practical exchange capacity is 1 mEq potassium per 1 g of resin in vivo, and in vitro capacity is 3.1 mEq of potassium per 1 g of resin, therefore, a wide range of exchange capacity exists such that close monitoring of serum electrolytes is necessary.</p></div>
<div class="block phk drugH1Div" id="F222017"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Hours to days</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: None</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Completely feces (primarily as potassium polystyrene sulfonate)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F222023"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Shi bang</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Elutit natrium</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Resonium natrium</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Resinokaten</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Kayexalate</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Kayexalate</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Kayexalate</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Resonium a</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Kionex | Sps</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Resonium A</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Pms sodium polystyrene sulfonate | PMS-Sodium Polystyrene Sulfonate | Resonium</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Resonium-a (kayexalate)</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Kayexalate | Resonium a</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Kayexalate</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Kexelate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24759345">
<a name="24759345"></a>Albeldawi M, Gaur V, Weber L. Kayexalate-induced colonic ulcer. <i>Gastroenterol Rep (Oxf)</i>. 2014;2(3):235-236. doi:10.1093/gastro/gou011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/24759345/pubmed" id="24759345" target="_blank">24759345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30202215">
<a name="30202215"></a>Almulhim AS, Hall E, Mershid Al Rehaili B, Almulhim AS. Sodium polystyrene sulfonate induced intestinal necrosis; a case report. <i>Saudi Pharm J</i>. 2018;26(6):771-774. doi:10.1016/j.jsps.2018.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/30202215/pubmed" id="30202215" target="_blank">30202215</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36619435">
<a name="36619435"></a>Angel-Korman A, Biton R, Rappoprt V, Hausmann M, Leiba A. An electrolyte flip flop - a patient with chronic hyperkalemic acidosis presenting with severe hypokalemic alkalosis. <i>Heliyon</i>. 2022;8(12):e12607. doi:10.1016/j.heliyon.2022.e12607<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/36619435/pubmed" id="36619435" target="_blank">36619435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26327703">
<a name="26327703"></a>Batterink J, Lin J, Au-Yeung SH, Cessford T. Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia. <i>Can J Hosp Pharm</i>. 2015;68(4):296-303. doi:10.4212/cjhp.v68i4.1469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/26327703/pubmed" id="26327703" target="_blank">26327703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1416324">
<a name="1416324"></a>Belanger DR, Tierney MG, and Dickinson G, “Effect of Sodium Polystyrene Sulfonate on Lithium Bioavailability,” <i>Ann Emerg Med</i>, 1992, 21(11):1312-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/1416324/pubmed" id="1416324" target="_blank">1416324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23329388">
<a name="23329388"></a>Cameron JC, Kennedy D, Feber J, Wong E, Geier P, Vaillancourt R. Pretreatment of infant formula with sodium polystyrene sulfonate: focus on optimal amount and contact time. <i>Paediatr Drugs</i>. 2013;15(1):43-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/23329388/pubmed" id="23329388" target="_blank">23329388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31706619">
<a name="31706619"></a>Clase CM, Carrero JJ, Ellison DH, et al; Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2020;97(1):42-61. doi:10.1016/j.kint.2019.09.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/31706619/pubmed" id="31706619" target="_blank">31706619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26230206">
<a name="26230206"></a>Croitoru M, Shouval A, Chepurov D, Katz Y. Giant intragastric sodium polystyrene sulfonate bezoar. <i>Kidney Int</i>. 2015;88(2):415. doi:10.1038/ki.2015.18<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/26230206/pubmed" id="26230206" target="_blank">26230206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33997091">
<a name="33997091"></a>Dantas E, Coelho M, Sequeira C, et al. Lower gastrointestinal bleeding associated with sodium polystyrene sulfonate use. <i>ACG Case Rep J</i>. 2021;8(5):e00585. doi:10.14309/crj.0000000000000585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/33997091/pubmed" id="33997091" target="_blank">33997091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37008520">
<a name="37008520"></a>Dos Santos FS, Aver GP, Paim TV, Riva F, Brambilla E, Soldera J. Sodium-polystyrene sulfonate-induced colitis. <i>GE Port J Gastroenterol</i>. 2021;30(2):153-155. doi:10.1159/000521195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/37008520/pubmed" id="37008520" target="_blank">37008520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30370313">
<a name="30370313"></a>Edhi AI, Cappell MS, Sharma N, Amin M, Patel A. One oral dose of sodium polystyrene sulfonate associated with ischemic colitis and crystal deposition in colonic mucosa. <i>ACG Case Rep J</i>. 2018;5:e74. doi:10.14309/crj.2018.74<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/30370313/pubmed" id="30370313" target="_blank">30370313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eichenwald.1">
<a name="Eichenwald.1"></a>Eichenwald EC, ed. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc,FSHP, FISAC; Michael Heung, MD, MS</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10649740">
<a name="10649740"></a>Fassinger N, Dabbagh S, Mukhopadhyay S, Lee DY. Mineral content of infant formula after treatment with sodium polystyrene sulfonate or calcium polystyrene sulfonate. <i>Adv Perit Dial</i>. 1998;14:274-277.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/10649740/pubmed" id="10649740" target="_blank">10649740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29680028">
<a name="29680028"></a>Faucon AL, Daudon M, Frochot V, Bazin D, Terris B, Caudwell V. Delayed ileal perforation from sodium polystyrene sulfonate. <i>Kidney Int</i>. 2018;93(5):1251-1252. doi:10.1016/j.kint.2017.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/29680028/pubmed" id="29680028" target="_blank">29680028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23255245">
<a name="23255245"></a>Fordjour KN, Walton T, Doran JJ. Management of hyperkalemia in hospitalized patients.<i> Am J Med Sci</i>. 2014;347(2):93-100. doi:10.1097/MAJ.0b013e318279b105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/23255245/pubmed" id="23255245" target="_blank">23255245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fuhrman.1">
<a name="Fuhrman.1"></a>Fuhrman B, Zimmerman J, eds.<i> Pediatric Critical Care</i>. 5th ed. Philadelphia, PA: Elsevier Health; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33100548">
<a name="33100548"></a>Garcia Rodriguez V, Grami Z, Laney J, Cai Z, Larson S. Esophageal necrosis associated with sodium polystyrene sulfonate (Kayexalate) use. <i>Proc (Bayl Univ Med Cent)</i>. 2020;33(4):624-626. doi:10.1080/08998280.2020.1801322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/33100548/pubmed" id="33100548" target="_blank">33100548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1496969">
<a name="1496969"></a>Gerstman BB, Kirkman R, Platt R. Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. <i>Am J Kidney Dis</i>. 1992;20(2):159.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/1496969/pubmed" id="1496969" target="_blank">1496969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26587776">
<a name="26587776"></a>Hagan AE, Farrington CA, Wall GC, Belz MM. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study. <i>Clin Nephrol</i>. 2016;85(1):38-43<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/26587776/pubmed" id="26587776" target="_blank">26587776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7059266">
<a name="7059266"></a>Haupt HM and Hutchins GM, “Sodium Polystyrene Sulfonate Pneumonitis,” <i>Arch Intern Med</i>, 1982, 142(2):379-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/7059266/pubmed" id="7059266" target="_blank">7059266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28959498">
<a name="28959498"></a>Kakajiwala A, Barton KT, Rampolla E, Breen C, Pradhan M. Acute hypocalcemia and metabolic alkalosis in children on cation-exchange resin therapy. <i>Case Rep Nephrol</i>. 2017;2017:6582613. doi:10.1155/2017/6582613<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/28959498/pubmed" id="28959498" target="_blank">28959498</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kayexalate.1">
<a name="Kayexalate.1"></a>Kayexalate (sodium polystyrene sulfonate) [prescribing information]. St. Michael, Barbados: Concordia Pharmaceutical Inc; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kionex.1">
<a name="Kionex.1"></a>Kionex (sodium polystyrene sulfonate) powder [prescribing information]. Minneapolis, MN: Perrigo; February 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kionex.2">
<a name="Kionex.2"></a>Kionex (sodium polystyrene sulfonate) suspension [prescribing information]. Minneapolis, MN: Perrigo; January 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33927869">
<a name="33927869"></a>Klasen JM, Peterson CJ, Fourie LL, et al. Small crystals with severe consequences. <i>J Surg Case Rep</i>. 2021;2021(4):rjab135. doi:10.1093/jscr/rjab135<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/33927869/pubmed" id="33927869" target="_blank">33927869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27215929">
<a name="27215929"></a>Lee J, Moffett BS. Treatment of pediatric hyperkalemia with sodium polystyrene sulfonate. <i>Pediatr Nephrol</i>. 2016;31(11):2113-2117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/27215929/pubmed" id="27215929" target="_blank">27215929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21181208">
<a name="21181208"></a>Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. <i>Pediatr Nephrol</i>. 2011;26(3):377-384.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/21181208/pubmed" id="21181208" target="_blank">21181208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26576619">
<a name="26576619"></a>Lepage L, Dufour AC, Doiron J, et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD. <i>Clin J Am Soc Nephrol</i>. 2015;10(12):2136-2142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/26576619/pubmed" id="26576619" target="_blank">26576619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1986079">
<a name="1986079"></a>Malone TA, “Glucose and Insulin Versus Cation-Exchange Resin for the Treatment of Hyperkalemia in Very Low Birth Weight Infants,” <i>J Pediatr</i>, 1991, 118(1):121-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/1986079/pubmed" id="1986079" target="_blank">1986079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19373153">
<a name="19373153"></a>McGowan CE, Saha S, Chu G, et al. Intestinal necrosis due to sodium polystyrene sulfonate (kayexalate) in sorbitol. <i>South Med J.</i> 2009;102(5):493-497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/19373153/pubmed" id="19373153" target="_blank">19373153</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32265601">
<a name="32265601"></a>Meyers RS, Thackray J, Matson KL, et al. <i>K</i>ey Potentially <i>I</i>nappropriate <i>D</i>rugs in Pediatrics: The KIDs List. <i>J Pediatr Pharmacol Ther</i>. 2020;25(3):175-191.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/32265601/pubmed" id="32265601" target="_blank">32265601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27048188">
<a name="27048188"></a>Mistry M, Shea A, Giguère P, Nguyen ML. Evaluation of sodium polystyrene sulfonate dosing strategies in the inpatient management of hyperkalemia. <i>Ann Pharmacother</i>. 2016;50(6):455-462.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/27048188/pubmed" id="27048188" target="_blank">27048188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12628894">
<a name="12628894"></a>Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” <i>Chest</i>, 2003, 123(3):897-922.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/12628894/pubmed" id="12628894" target="_blank">12628894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mount.1">
<a name="Mount.1"></a>Mount DB. Treatment and prevention of hyperkalemia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 22, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21694940">
<a name="21694940"></a>Nepal M, Bucaloiu ID, Norfolk ER. Hypernatremia in a patient treated with sodium polystyrene sulfonate. <i>Int J Nephrol Renovasc Dis</i>. 2010;3:141-143. doi:10.2147/IJNRD.S13871<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/21694940/pubmed" id="21694940" target="_blank">21694940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180477">
<a name="31180477"></a>Noel JA, Bota SE, Petrcich W, et al. Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. <i>JAMA Intern Med.</i> 2019;179(8):1025-1033. doi:10.1001/jamainternmed.2019.0631<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/31180477/pubmed" id="31180477" target="_blank">31180477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180445">
<a name="31180445"></a>Parks M, Grady D. Sodium polystyrene sulfonate for hyperkalemia. <i>JAMA Intern Med</i>. 2019;179(8):1023-1024. doi:10.1001/jamainternmed.2019.1291<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/31180445/pubmed" id="31180445" target="_blank">31180445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31180445">
<a name="31180445"></a>Piron L, Ramos J, Taourel P. Colonic perforation associated with sodium polystyrene sulfonate (Kayexalate) use. <i>Diagn Interv Imaging</i>. 2018;99(7-8):507-509. doi:10.1016/j.diii.2018.02.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/31180445/pubmed" id="31180445" target="_blank">31180445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15080600">
<a name="15080600"></a>Rivard AL, Raup SM, Beilman GJ. Sodium polystyrene sulfonate used to reduce the potassium content of a high-protein enteral formula: a quantitative analysis. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(2):76-78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/15080600/pubmed" id="15080600" target="_blank">15080600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sunrise.1">
<a name="Sunrise.1"></a>Sodium polystyrene sulfonate powder for suspension [prescribing information]. Rahway. NJ: Sunrise Pharmaceutical, Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WestWard.1">
<a name="WestWard.1"></a>Sodium polystyrene sulfonate suspension [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals Corp; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25930981">
<a name="25930981"></a>Taylor JM, Oladitan L, Carlson S, Hamilton-Reeves JM. Renal formulas pretreated with medications alters the nutrient profile. <i>Pediatr Nephrol</i>. 2015;30(10):1815-1823.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/25930981/pubmed" id="25930981" target="_blank">25930981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23707305">
<a name="23707305"></a>Thompson K, Flynn J, Okamura D, Zhou L. Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency. <i>J Ren Nutr</i>. 2013;23(5):333-339.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/23707305/pubmed" id="23707305" target="_blank">23707305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1416323">
<a name="1416323"></a>Tomaszewski C, Musso C, Pearson JR, et al, “Lithium Absorption Prevented by Sodium Polystyrene Sulfonate in Volunteers,” <i>Ann Emerg Med</i>, 1992, 21(11):1308-11.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/1416323/pubmed" id="1416323" target="_blank">1416323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27018102">
<a name="27018102"></a>Usta Y, Ramirez C, Dennert B. Emphysematous gastritis and necrosis as a result of orally ingested sodium polystyrene sulfonate (kayexalate) in sorbitol.<i> Am J Gastroenterol.</i> 2016;111(3):309.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/27018102/pubmed" id="27018102" target="_blank">27018102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17253550">
<a name="17253550"></a>Vemgal P and Ohlsson A, "Interventions for Non-Oliguric Hyperkalaemia in Preterm Neonates," <i>Cochrane Database Syst Rev</i>, 2007, (1):CD005257.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/17253550/pubmed" id="17253550" target="_blank">17253550</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18425722">
<a name="18425722"></a>Yaseen H, Khalaf M, Dana A, et al, "Salbutamol Versus Cation-Exchange Resin (Kayexalate) for the Treatment of Nonoliguric Hyperkalemia in Preterm Infants," <i>Am J Perinatol</i>, 2008, 25(3):193-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/18425722/pubmed" id="18425722" target="_blank">18425722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24172749">
<a name="24172749"></a>Zaidan M, Loupy A, Rouquette A, et al. A kidney transplant patient with ileocecal inflammation. Sodium polystyrene sulfonate-associated intestinal ulcer and foreign-body reaction. <i>Kidney Int</i>. 2013;84(5):1057-1059. doi:10.1038/ki.2013.146<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-polystyrene-sulfonate-drug-information/abstract-text/24172749/pubmed" id="24172749" target="_blank">24172749</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9936 Version 168.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
